Epstein Secrets

umans; and the M.I.T. theoretical physicist Frank Wilczek, a Nobel laureate. The lure for some of the scie

Church, a molecular engineer who has worked to identify genes that could be altered to create superior humans; and the M.I.T. theoretical physicist Frank Wilczek, a Nobel laureate. The lure for some of the scientists was Mr. Epstein's money. He dangled financing for their pet projects. Some of the scientists

regulators. But in 2017, the company practically beamed that it had "received clearance from the U.S. Food and Drug Administration for the Company's Investigational New Drug (IND) application lodged last month." The fact that Collins' role in the legislation could also have benefited other companies — and may even have been

umans; and the M.I.T. theoretical physicist Frank Wilczek, a Nobel laureate. The lure for some of the scie

Church, a molecular engineer who has worked to identify genes that could be altered to create superior humans; and the M.I.T. theoretical physicist Frank Wilczek, a Nobel laureate. The lure for some of the scientists was Mr. Epstein's money. He dangled financing for their pet projects. Some of the scientists

regulators. But in 2017, the company practically beamed that it had "received clearance from the U.S. Food and Drug Administration for the Company's Investigational New Drug (IND) application lodged last month." The fact that Collins' role in the legislation could also have benefited other companies — and may even have been

umans; and the M.I.T. theoretical physicist Frank Wilczek, a Nobel laureate. The lure for some of the scie

Church, a molecular engineer who has worked to identify genes that could be altered to create superior humans; and the M.I.T. theoretical physicist Frank Wilczek, a Nobel laureate. The lure for some of the scientists was Mr. Epstein's money. He dangled financing for their pet projects. Some of the scientists

regulators. But in 2017, the company practically beamed that it had "received clearance from the U.S. Food and Drug Administration for the Company's Investigational New Drug (IND) application lodged last month." The fact that Collins' role in the legislation could also have benefited other companies — and may even have been